Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

23 Jul 2012 14:47

RNS Number : 2855I
Fastnet Oil & Gas PLC
23 July 2012
 



 

 

Standard Form TR-1Voting rights attached to shares- Article 12(1) of directive 2004/109/ECFinancial instruments - Article 11(3) of the Commission Directive 2007/14/EC[i]

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached [ii]:

 

Fastnet Oil and Gas

 

2. Reason for the notification (please tick the appropriate box or boxes):

[x ] an acquisition or disposal of voting rights

[ ] an acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

[ ] an event changing the breakdown of voting rights

3. Full name of person(s) subject to the notification obligation[iii]:

J&E Davy T/A Davy

 

4. Full name of shareholder(s) (if different from 3.)[iv]:

 

5. Date of the transaction and date on which the threshold is crossed or reached[v]:

20 July 2012

 

6. Date on which issuer notified;

23 July 2012

 

7. Threshold(s) that is/are crossed or reached:

3%

8. Notified details:

 

1.

1. 1. 1.

A) Voting rights attached to shares

Class/type of shares (if possible using the ISIN CODE)

Situation previous to the Triggering transaction [vi]

Resulting situation after the triggering transaction[vii]

Number of Shares[viii]

Number of Voting rights[ix]

Number of shares[x]

Number of voting rights[xi]

% of voting rights

Direct

Direct[xii]

Indirect[xiii]

Direct

Indirect

GB00B85HRF56

Below 3%

4,485,538

 

 

4,485,538

 

2.72%

SUBTOTAL A (based on aggregate voting rights)

Below 3%

4,485,538

 

4,485,538

 

2.72%

 

B) Financial Instruments

Resulting situation after the triggering transaction[xiv]

Type of financial instrument

Expiration Date[xv]

Exercise/Conversion Period/ Date[xvi]

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

SUBTOTAL B (in relation to all expiration dates)

 

Total (A+B)

number of voting rights

% of voting rights

4,485,538

 

2.72%

 

9. Chain of controlled undertakings through which the voting rights and/or the financial instrumentsare effectively held, if applicable[xvii]:

10. In case of proxy voting:[name of the proxy holder] will cease to hold [number] voting rights as of [date].

11. Additional information:

Done at [place] on [date].

 


[i] This form is to be sent to the issuer or underlying issuer and to be filed with the competent authority.

 

[ii] Either the full name of the legal entity or another method for identifying the issuer or underlying issuer, provided it is reliable and accurate.

 

[iii] This should be the full name of (a) the shareholder; (b) the natural person or legal entity acquiring, disposing of or exercising voting rights in the cases provided for in Article 10 (b) to (h) of Directive 2004/109/EC; (c) all the parties to the agreement referred to in Article 10 (a) of that Directive, or (d) the holder of financial instruments entitled to acquire shares already issued to which voting rights are attached, as appropriate.

 

In relation to the transactions referred to in points (b) to (h) of Article 10 of that Directive, the following list is provided as indication of the persons who should be mentioned:

 

- in the circumstances foreseen in letter (b) of Article 10 of that Directive, the natural person or legal entity that acquires the voting rights and is entitled to exercise them under the agreement and the natural person or legal entity who is transferring temporarily for consideration the voting rights;

 

- in the circumstances foreseen in letter (c) of Article 10 of that Directive, the natural person or legal entity holding the collateral, provided the person or entity controls the voting rights and declares its intention of exercising them, and natural person or legal entity lodging the collateral under these conditions;

 

- in the circumstances foreseen in letter (d) of Article 10 of that Directive, the natural person or legal entity who has a life interest in shares if that person or entity is entitled to exercise the voting rights attached to the shares and the natural person or legal entity who is disposing of the voting rights when the life interest is created;

 

- in the circumstances foreseen in letter (e) of Article 10 of that Directive, the controlling natural person or legal entity and, provided it has a notification duty at an individual level under Article 9, under letters (a) to (d) of Article 10 of that Directive or under a combination of any of those situations, the controlled undertaking;

 

- in the circumstances foreseen in letter (f) of Article 10 of that Directive, the deposit taker of the shares, if he can exercise the voting rights attached to the shares deposited with him at his discretion, and the depositor of the shares allowing the deposit taker to exercise the voting rights at his discretion;

 

- in the circumstances foreseen in letter (g) of Article 10 of that Directive, the natural person or legal entity that controls the voting rights;

 

- in the circumstances foreseen in letter (h) of Article 10 of that Directive, the proxy holder, if he can exercise the voting rights at his discretion, and the shareholder who has given his proxy to the proxy holder allowing the latter to exercise the voting rights at his discretion.

[iv] Applicable in the cases provided for in Article 10 (b) to (h) of Directive 2004/109/EC. This should be the full name of the shareholder who is the counterparty to the natural person or legal entity referred to in Article 10 of that Directive unless the holdings of the shareholder would be lower than 5% of the total number of voting rights.

 

[v] The date of the transaction should normally be, in the case of an on exchange transaction, the date on which the matching of orders occurs; in the case of an off exchange transaction, date of the entering into an agreement. 

 

The date on which threshold is crossed should normally be the date on which the acquisition, disposal or possibility to exercise voting rights takes effect. For passive crossings, the date when the corporate event took effect.

 

[vi] Please refer to the situation disclosed in the previous notification. In case the situation previous to the triggering transaction was below 3%, please state "below 3%".

 

[vii] If the holding has fallen below the minimum threshold, the notifying party should not be obliged to disclose the extent of the holding, only that the new holding is below 3%.

 

For the case provided for in Article 10(a) of Directive 2004/109/EC, there should be no disclosure of individual holdings per party to the agreement unless a party individually crosses or reaches an Article 9 threshold. This applies upon entering into, introducing changes to or terminating an agreement.

 

[viii] To be used in Member States where applicable.

 

[ix] Direct and indirect.

 

[x] To be used in Member States where applicable.

 

[xi] In case of combined holdings of shares with voting rights attached "direct holding" and voting rights "indirect holding", please split the voting rights number and percentage into the direct and indirect columns - if there is no combined holdings, please leave the relevant box blank.

 

[xii] Voting rights attached to shares held by the notifying party (Article 9 of Directive 2004/109/EC).

 

[xiii] Voting rights held by the notifying party independently of any holding of shares (Article 10 of Directive 2004/109/EC).

 

[xiv] If the holding has fallen below the minimum threshold, the notifying party should not be obliged to disclose the extent of the holding, only that the new holding is below 3%.

 

[xv] Date of maturity/expiration of the financial instrument i.e. the date when right to acquire shares ends.

 

[xvi] If the financial instrument has such a period - please specify this period - for example once every 3 months starting from [date].

 

[xvii] The notification should include the name(s) of the controlled undertakings through which the voting rights are held. The notification should also include the amount of voting rights and the percentage held by each controlled undertaking, insofar as individually the controlled undertaking holds 3% or more, and insofar as the notification by the parent undertaking is intended to cover the notification obligations of the controlled undertaking.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLPGUACMUPPGWW
Date   Source Headline
7th Jan 20197:00 amRNSPositive results for gene therapy AP103
4th Jan 201912:56 pmRNSEASE Phase III trial interim efficacy results
21st Dec 20182:05 pmRNSSecond Price Monitoring Extn
21st Dec 20182:00 pmRNSPrice Monitoring Extension
19th Dec 20187:00 amRNSUpdate on ongoing AP101 Trial
10th Dec 201811:30 amRNSGrant Funding from Irish Government for AP103
17th Oct 20187:00 amRNSLojuxta to be reimbursed in France
26th Sep 20187:00 amRNSInterim Results
14th Sep 20187:00 amRNSNotice of Results
10th Sep 20187:00 amRNSAmryt receives IND approval from FDA for AP101
2nd Aug 20187:00 amRNSFDA grants Pediatric Rare Disease designation
19th Jul 20187:00 amRNSTrading update & significant momentum building
9th Jul 20187:00 amRNSNHS England approves funding for Lojuxta
6th Jul 20187:00 amRNSChange of Registered Address
25th Jun 20188:10 amRNSCompany name alteration for previous release
25th Jun 20187:00 amRNSPositive data of Pollinex Quattro Grass vaccine
5th Jun 201810:41 amRNSResult of AGM
29th May 20187:00 amRNSFour Middle East Lojuxta® Distribution Agreements
10th May 20187:00 amRNSExclusive Lojuxta® Licence Expanded
9th May 20182:48 pmRNSHolding(s) in Company
8th May 20187:00 amRNSHolding(s) in Company and Lock-in agreement
4th May 20187:00 amRNSPosting of Annual Report 2017 and Notice of AGM
17th Apr 20187:00 amRNSFinal Results
15th Mar 20187:00 amRNSTrading update & Gene therapy agreement
6th Mar 20187:00 amRNSSenior Management Appointment
6th Mar 20187:00 amRNSDistribution Agreement for Lojuxta in Middle East
2nd Mar 20187:00 amRNSNotice of Trading Update
30th Jan 20187:00 amRNSNew Distribution Agreement Signed
24th Jan 20187:00 amRNSSenior Management Team Appointment
10th Jan 20187:00 amRNSNew Distribution Agreement Signed
8th Jan 20187:00 amRNSDistribution Agreement Signed Covering Switzerland
20th Dec 20177:00 amRNSSenior Management Team Appointment
1st Dec 20177:00 amRNSGrant of Options & PDMR Dealings
20th Nov 20174:35 pmRNSPrice Monitoring Extension
13th Nov 20177:00 amRNSDistribution Agreement Signed in Saudi Arabia
13th Oct 20173:29 pmRNSHolding(s) in Company
11th Oct 20177:00 amRNSDirector Share Purchases
11th Oct 20177:00 amRNSHolding(s) in Company
11th Oct 20177:00 amRNSEnterprise Securities Market Notice
10th Oct 20177:00 amRNSEnterprise Securities Market Notice
9th Oct 201712:13 pmRNSResult of General Meeting & Completion of Placing
21st Sep 20177:00 amRNSPlacing to raise EUR 15m
4th Sep 20177:00 amRNSInterim Results
31st Aug 20177:00 amRNSAttendance at Rodman & Renshaw Conference
30th Aug 20177:00 amRNSSenior Management Appointment
23rd Aug 20178:30 amRNSNotice of Results
25th Jul 20177:00 amRNSHighly positive long-term study results - Lojuxta
25th May 201711:49 amRNSResult of AGM
25th May 20177:00 amRNSAGM Statement
27th Apr 20177:00 amRNSStudy Results of Real-World Experience of Lojuxta

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.